These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37748107)

  • 1. Efficacy of ESHAP versus ICE plus dexamethasone (DICE) as salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
    Boonlerd P; Tantiworawit A; Norasetthada L; Chai-Adisaksopha C; Punnachet T; Hantrakun N; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Rattarittamrong E
    Ann Med; 2023; 55(2):2261109. PubMed ID: 37748107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of modified rituximab-ESHAP therapy for relapsed/refractory B-cell lymphoma.
    Ueda K; Nannya Y; Asai T; Yamamoto G; Hangaishi A; Takahashi T; Imai T; Kurokawa M
    J Chemother; 2010 Feb; 22(1):54-7. PubMed ID: 20227994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.
    Martín A; Redondo AM; Dlouhy I; Salar A; González-Barca E; Canales M; Montes-Moreno S; Ocio EM; López-Guillermo A; Caballero D;
    Br J Haematol; 2016 Apr; 173(2):245-52. PubMed ID: 26847165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
    Martín A; Conde E; Arnan M; Canales MA; Deben G; Sancho JM; Andreu R; Salar A; García-Sanchez P; Vázquez L; Nistal S; Requena MJ; Donato EM; González JA; León A; Ruiz C; Grande C; González-Barca E; Caballero MD;
    Haematologica; 2008 Dec; 93(12):1829-36. PubMed ID: 18945747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy and survival analysis of DICE regimen for 97 patients with relapsed or refractory Non-Hodgkin's lymphoma].
    Ping LY; Song YQ; Zheng W; Wang XP; Xie Y; Lin NJ; Tu MF; Ying ZT; Liu WP; Zhang C; Deng LJ; Zhu J
    Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):790-794. PubMed ID: 27719723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma.
    Mehrzad V; Ashrafi F; Farrashi AR; Pourmarjani R; Dehghani M; Shahsanaei A
    Adv Biomed Res; 2017; 6():30. PubMed ID: 28401077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma.
    Kim DY; Nam J; Chung JS; Kim SW; Shin HJ
    Cancer Res Treat; 2022 Jan; 54(1):301-313. PubMed ID: 33940789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine and treatment of diffuse large B-cell lymphoma in relapsed or refractory elderly patients: a prospective randomized trial in Algeria.
    Aribi M; Mesli N; Remla N; Sari BE; Taleb A; Touhami H; Bekadja MA; Zouaoui-Benhadji Z; Bouzid K; Meguenni K
    J Cancer Res Ther; 2010; 6(1):41-6. PubMed ID: 20479546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma.
    del Rio MS; Choquet S; Hoang-Xuan K; Glaisner S; Fourme E; Janvier M; Soussain C
    J Neurooncol; 2011 Nov; 105(2):409-14. PubMed ID: 21656329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma.
    Bi J; Espina BM; Tulpule A; Boswell W; Levine AM
    J Acquir Immune Defic Syndr; 2001 Dec; 28(5):416-21. PubMed ID: 11744828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
    Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
    Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ESHAP versus rituximab-ESHAP in frail patients with refractory diffuse large B-cell lymphoma.
    Avilés A; Neri N; Huerta-Guzmán J; de Jesús Nambo M
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):125-8. PubMed ID: 20371445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone.
    Simpson L; Ansell SM; Colgan JP; Habermann TM; Inwards DJ; Ristow KM; Johnston PB; Markovic SN; Micallef IN; Porrata LF; Witzig TE
    Leuk Lymphoma; 2007 Jul; 48(7):1332-7. PubMed ID: 17613762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma.
    Puig N; Wang L; Seshadri T; al-Farsi K; Keating A; Crump M; Kuruvilla J
    Leuk Lymphoma; 2013 Mar; 54(3):507-13. PubMed ID: 22897731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
    Harting R; Venugopal P; Gregory SA; O'brien T; Bogdanova E
    Clin Lymphoma Myeloma; 2007 May; 7(6):406-12. PubMed ID: 17621406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of R-ESHAP as salvage therapy in refractory/relapsed follicular lymphoma: a real-world experience on behalf of GELCAB group.
    Muntañola A; Baumann T; Caballero AC; Sánchez-González B; Mercadal S; Escoda L; Soler A; Iserte L; Canet M; Villalobos MT; Magnano L; Sorigué M; García O; Salar A; López-Guillermo A; Sancho JM
    Ann Hematol; 2020 Jul; 99(7):1627-1634. PubMed ID: 32451707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO.
    Martín García-Sancho A; Baile M; Rodríguez G; Dlouhy I; Sancho JM; Jarque I; González-Barca E; Salar A; Espeso M; Grande C; Bergua J; Montes-Moreno S; Redondo A; Enjuanes A; Campo E; López-Guillermo A; Caballero D
    Br J Haematol; 2023 Oct; 203(2):202-211. PubMed ID: 37485564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma.
    Labrador J; Cabrero-Calvo M; Pérez-López E; Mateos MV; Vázquez L; Caballero MD; García-Sanz R
    Ann Hematol; 2014 Oct; 93(10):1745-53. PubMed ID: 24863692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1 blockade combined with ICE regimen in relapsed/refractory diffuse large B-cell lymphoma.
    Ping L; Gao Y; He Y; Bai B; Huang C; Shi L; Wang X; Huang H
    Ann Hematol; 2023 Aug; 102(8):2189-2198. PubMed ID: 37306710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.